Agency / Source: Werbeagentur & PR-Agentur co-operate

Check Ads Availability|e-mail Article

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!

Utilising Cost Reduction Opportunities - Conference on 'Optimising Stability Testing' in London - International experts discussed how to realise more efficient stability tests for medicinal products last Thursday and Friday (18 and 19 September) in London
Utilising Cost Reduction Opportunities - Conference on 'Optimising Stability Testing' in London

 

PRZOOM - /newswire/ - Muenster, North Rhine-Westfalia, Germany, 2008/09/26 - International experts discussed how to realise more efficient stability tests for medicinal products last Thursday and Friday (18 and 19 September) in London.

   
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

International experts discussed how to realise more efficient stability tests for medicinal products last Thursday and Friday (18 and 19 September) in London. At the two-day "Optimising Stability Testing" conference Dr Sven Oliver Kruse, managing director of Diapharm Analytics GmbH, was one of those explaining how the burden of ongoing stability tests can be reduced with improved study design. All medicinal products on the market must be monitored in a continuous programme in order to demonstrate stability and quality over their entire market life.

"Laboratory analysis is a cost factor that still offers room for manoeuvre in many companies" reported Dr Sven Oliver Kruse. The flexibility in the EU GMP guideline on "Ongoing stability" in particular offers opportunities for improved efficiency. For example, for generally identical medicinal products with a similar primary packaging but different strengths the guideline permits group building within the concept of "bracketing". If justified, it is also permitted to reduce the frequency of tests recognised as noncritical. "However, it is important to know possible pitfalls and to make an individual risk-benefit assessment for each product," Dr. Kruse emphasised.

At the "Optimising Stability Testing" conference a total of 14 speakers described a variety of options for optimising stability testing – from the form of the study design, through analytical and statistical evaluation procedures, data and report management systems up to outsourcing. Pharmaceutical industry chief executives and senior staff from Europe, North America and Africa, from company laboratories and from service providers attended the conference in London initiated by Visiongain.

 
 
Your Banner Ad Here instead - Showing along with ALL Articles covering Pharma / BioTech / Nutrition Announcements

Replace these Affiliate Programs at ANYTIME! Your banner here within the next hour. Learn How!


 

Agency / Source: Werbeagentur & PR-Agentur co-operate

 
 

Availability: All Regions (Including Int'l)

 

Traffic Booster: [/] Quick PRZOOM - Press & Newswire Visibility Checker

 

Distribution / Indexing: [+]

 
 
# # #
 

 
  Your Banner Ad showing on ALL
Pharma / BioTech / Nutrition articles,
CATCH Visitors via Your Competitors Announcements!


Utilising Cost Reduction Opportunities - Conference on 'Optimising Stability Testing' in London

Company website links NOT available to basic submissions
It is OK to republish and/or LINK any newswire for any legitimate media purpose as long as you name PRZOOM - Press & Newswire and LINK as the source.
 
  For more information, please visit:
Is this your article? Activate ALL web links by Upgrading to Press Release PREMIUM Plan Now!
|
Contact: Christian Rieke - Co-Operate.net 
 
PRZOOM / PRTODAY - Newswire Today disclaims any content contained in this article. If you need/wish to contact the company who published the current release, you will need to contact them - NOT us. Issuers of articles are solely responsible for the accuracy of their content. Our complete disclaimer appears here.
IMPORTANT INFORMATION: Issuance, publication or distribution of this press release in certain jurisdictions could be subject to restrictions. The recipient of this press release is responsible for using this press release and the information herein in accordance with the applicable rules and regulations in the particular jurisdiction. This press release does not constitute an offer or an offering to acquire or subscribe for any Werbeagentur & PR-Agentur co-operate securities in any jurisdiction including any other companies listed or named in this release.

Pharma / BioTech / Nutrition via RSSAdd NewswireToday - PRZOOM Headline News to FeedBurner
Find who RetweetFollow @NewswireTODAY

Are you the owner of this article?, Turn it PREMIUM with your LOGO instead - and make it 3rd party Ads-Free! within the next hour!


Read Latest Press Releases From Werbeagentur & PR-Agentur co-operate / Company Profile


Read Pharma / BioTech / Nutrition Most Recent Related Press Releases:

Ono Pharma Announces New Drug Discovery Collaboration with Congruence Therapeutics in the Priority Areas of Neurology and Immunology
Ono Pharma Announces Transfer of the Manufacturing and Marketing Approval Authorization for Opalmon® Tablets and Prostandin® Ointment
Ono Announces U.S. Food and Drug Administration Acceptance for Filing of New Drug Application for Tirabrutinib in Patients with Relapsed or Refractory
SCHOTT Pharma Launches EVERIC® Lyo & Amber Vials for Light-sensitive ADCs
Arbitration Tribunal Upholds Ipsen’s Termination of R&D Agreement with Galderma
New Data Reinforces Ipsen’s Commitment to Bringing Solutions and Addressing Care Gaps in Neurological Diseases At TOXINS
Opdivo® Intravenous Infusion Approved in Taiwan in Combination with Yervoy® for the Treatment of Adult Patients
U.S. FDA Grants Ipsen’s IPN60340 (ICT01) Breakthrough Therapy Designation in First Line Unfit Acute Myeloid Leukemia
Additional Approval of Combination Therapy with BRAFTOVI® Capsule, a BRAF Inhibitor, for the Indication of Colorectal Cancer in South Korea
BostonGene Recognized by Frost & Sullivan for 2025 Global Technology Innovation Leadership in AI-Driven Precision Oncology Solutions

Boost Your Social Network
& Crowdfunding Campaigns


LIFETIME SOCIAL MEDIA WALL
 
NewswireToday Celebrates 10 Years in Business
.



PREMIUM Members


Visit  BizJobs.com

Visit  JobsWare.com

Visit  RightITnow, Inc.







 
  ©2005-2026 PRZOOM - Limelon Advertising, Co.
Home | About PRZOOM | Advertise/Pricing | Contact | Investors | Privacy/TOS | Sitemap | FRANCAIS
newswire, PR press releases distribution service magazines engine news alert newsroom press room breaking news public relations articles company news alerts newswiredistribution ezine bizentrepreneur biznewstoday digital business report market search pr firms agencies reports distri-bution today investor relation successful internet entrepreneur newswire distribution prtoday.com freenewswiredistribution asianewstoday bizwiretoday USA pr UK today